<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soureas, K.</style></author><author><style face="normal" font="default" size="100%">Malandrakis, P.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, M. A.</style></author><author><style face="normal" font="default" size="100%">Minopoulos, C.</style></author><author><style face="normal" font="default" size="100%">Ntanasis-Stathopoulos, I.</style></author><author><style face="normal" font="default" size="100%">Liacos, C. I.</style></author><author><style face="normal" font="default" size="100%">Gavriatopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome</style></title><secondary-title><style face="normal" font="default" size="100%">Blood Cancer Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">*Multiple Myeloma/genetics/mortality/pathology/therapy/diagnosis</style></keyword><keyword><style  face="normal" font="default" size="100%">*Plasma Cells/metabolism/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">*Syndecan-1/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar 15</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">41</style></pages><isbn><style face="normal" font="default" size="100%">2044-5385 (Electronic)2044-5385 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The persistence of high relapse rates and therapy resistance continues to challenge the effective management of multiple myeloma (MM). The identification of novel MM-specific molecular markers could ameliorate risk-stratification tools and accurately identify high-risk patients towards personalized prognosis and therapy. miRNA-seq analysis of CD138+ plasma cells (n = 24) unveiled miR-221-3p and miR-222-3p (miR-221/222 cluster) as the most downregulated miRNAs in R-ISS III compared to R-ISS I/II patients. Subsequently, miR-221/222 levels were quantified by RT-qPCR in CD138+ plasma cells of our screening cohort (n = 141), assessing patients' mortality and disease progression as clinical endpoints. Internal validation was performed by bootstrap analysis, while clinical benefit was estimated by decision curve analysis. Kryukov et al. (n = 149) and Aass et al. (n = 86) served as institutional-independent validation cohorts. Loss of miR-221/222 cluster was strongly associated with patients' short-term progression and poor overall survival, which was confirmed by Kryukov et al. and Aass et al. validation cohorts. Intriguingly, miR-221/222-fitted multivariate models offered superior risk-stratification within R-ISS staging and risk-based cytogenetics. Moreover, miR-221/222 loss could effectively discriminate optimal 1st-line treatment responders with inferior treatment outcome. Our study identified the loss of miR-221/222 cluster as a powerful independent predictor of patients' post-treatment progression, ameliorating prognosis and supporting precision medicine in MM.</style></abstract><accession-num><style face="normal" font="default" size="100%">40089465</style></accession-num><notes><style face="normal" font="default" size="100%">Soureas, KonstantinosMalandrakis, PanagiotisPapadimitriou, Maria-AlexandraMinopoulos, ChristosNtanasis-Stathopoulos, IoannisLiacos, Christine-IvyGavriatopoulou, MariaKastritis, EfstathiosDimopoulos, Meletios-AthanasiosScorilas, AndreasAvgeris, MargaritisTerpos, EvangelosengProject 101097094/European Commission (EC)/Research Support, Non-U.S. Gov't2025/03/16 12:43Blood Cancer J. 2025 Mar 15;15(1):41. doi: 10.1038/s41408-025-01248-2.</style></notes><custom2><style face="normal" font="default" size="100%">PMC11910569</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, &quot;P. &amp; A. Kyriakou&quot; Children's Hospital, Athens, Greece.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. mavgeris@med.uoa.gr.Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, &quot;P. &amp; A. Kyriakou&quot; Children's Hospital, Athens, Greece. mavgeris@med.uoa.gr.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece. eterpos@med.uoa.gr.</style></auth-address></record></records></xml>